Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II preoperative radiotherapy with capecitabine and oxaliplatin for rectal cancer
ChiCTR-OIC-17011632Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Pathological complete response. Started Feb 2007; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR-OIC-17011632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17011632.